MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Baricitinib

CAS No. : 1187594-09-7

MCE 站：Baricitinib

产品活性：Baricitinib (LY3009104; INCB028050) 是选择性，可口服的 JAK1 和 JAK2 抑制剂，IC₅₀ 分别为5.9 nM 和 5.7 nM。

研究领域：Epigenetics  |  Stem Cell/Wnt  |  JAK/STAT Signaling

作用靶点：JAK

In Vitro: In cell-based assays, Baricitinib (INCB028050) proves to be a potent inhibitor of JAK signaling ａnd function. In PBMCs, Baricitinib inhibits IL-6-stimulated phosphorylation of the canonical substrate STAT3 (pSTAT3) ａnd subsequent production of the chemokine MCP-1 with IC₅₀ values of 44 nM ａnd 40 nM, respectively. In isolated naive T-cells, INCB028050 also inhibits pSTAT3 stimulated by IL-23 (IC₅₀=20 nM). Importantly, this inhibition prevented the production of two pathogenic cytokines (IL-17 ａnd IL-22) produced by Th17 cells-a subtype of helper T cells with demonstrable inflammatory ａnd pathogenic properties-with an IC₅₀ value of 50 nM. In stark contrast, the structurally similar but ineffective JAK1/2 inhibitors INCB027753 ａnd INCB029843 has no significant effect in any of these assays systems when tested at concentrations up to 10 μM.

In Vivo: Baricitinib (INCB028050) treatment, compares with vehicle, inhibits the increase in hind paw volumes during the 2 wk of treatment by 50% at a dose of 1 mg/kg ａnd >95% at doses of 3 or 10 mg/kg. Because baseline paw volume measurements are taken on treatment day 0-in animals with significant signs of disease-it is possible to have >100% inhibition in animals showing marked improvement in swelling. Baricitinib (0.7 mg/day) treated mice exhibits substantially reduced inflammation as assessed by H&E staining, reduced CD8 infiltration, ａnd reduced MHC class I ａnd class II expression when compared with vehicle-control treated mice. CD8⁺NKG2D⁺ cells, critical effectors of disease in murine ａnd human alopecia areata (AA), are greatly diminished in Baricitinib treated mice compare with vehicle control treated mice.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Immunology/Inflammation Compound Library  |  JAK/STAT Compound Library  |  Kinase Inhibitor Library  |  Stem Cell Signaling Compound Library  |  FDA-Approved Drug Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  AG490  |  Upadacitinib  |  AT9283  |  Gandotinib  |  Lestaurtinib  |  Oclacitinib maleate  |  JANEX-1  |  Cucurbitacin I  |  XL019  |  Atractylenolide I  |  FLLL32  |  Brevilin A  |  LFM-A13  |  Ginsenoside Rk1  |  ZM39923 hydrochloride  |  WHI-P154  |  Curculigoside  |  FM-381  |  RO8191  |  Reticuline  |  Ilginatinib maleate  |  TCS 21311  |  WHI-P97  |  Protosappanin A  |  Coumermycin A1  |  Dehydrocrenatidine  |  Delphinidin chloride  |  FM-479  |  NSC 33994

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。